Should I buy or sell Anebulo Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares. View ANEB analyst ratings or view top-rated stocks .

What is Anebulo Pharmaceuticals' stock price target for 2024?

3 analysts have issued 1 year price objectives for Anebulo Pharmaceuticals' stock. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's share price to reach $6.67 in the next year. This suggests a possible upside of 133.9% from the stock's current price. View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts .

How have ANEB shares performed in 2024?

Anebulo Pharmaceuticals' stock was trading at $2.42 at the start of the year. Since then, ANEB stock has increased by 17.8% and is now trading at $2.85. View the best growth stocks for 2024 here .

Are investors shorting Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 18,800 shares, an increase of 308.7% from the March 15th total of 4,600 shares. Based on an average trading volume of 5,600 shares, the short-interest ratio is presently 3.4 days. Currently, 0.2% of the company's shares are sold short. View Anebulo Pharmaceuticals' Short Interest .

When is Anebulo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANEB earnings forecast .

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its earnings results on Tuesday, February, 13th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11).

When did Anebulo Pharmaceuticals IPO?

Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ANEB

Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free ANEB Stock Alerts

$2.85

-0.15 (-5.00%)

(As of 03:26 PM ET)

Compare

Today's Range: $2.83
▼
$3.30
50-Day Range: $2.40
▼
$3.04
52-Week Range: $1.62
▼
$4.05

Volume: 4,903 shs
Average Volume: 5,573 shs
Market Capitalization: $73.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.67

Get Anebulo Pharmaceuticals alerts:

Anebulo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 133.9% Upside
$6.67 Price Target
Short Interest: Healthy
0.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.47) to ($0.52) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.03 out of 5 stars

Medical Sector

788th out of 919 stocks

Pharmaceutical Preparations Industry

354th out of 415 stocks

3.5

Analyst's Opinion

Consensus Rating
Anebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Anebulo Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.20% of the float of Anebulo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Anebulo Pharmaceuticals has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Anebulo Pharmaceuticals has recently increased by 308.70%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Anebulo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Anebulo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ANEB.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
85.90% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 28.40% of the stock of Anebulo Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.47) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anebulo Pharmaceuticals is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anebulo Pharmaceuticals is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anebulo Pharmaceuticals has a P/B Ratio of 6.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

ANEB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANEB Stock News Headlines

April 17, 2024 | morningstar.com

Anebulo Pharmaceuticals Inc 214

April 2, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Acrivon Therapeutics, Inc. (ACRV), Abivax SA Sponsored ADR (ABVX)

April 18, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

February 26, 2024 | msn.com

Milestone rallies 23% on FDA update for tachycardia drug

February 16, 2024 | markets.businessinsider.com

Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track

February 15, 2024 | msn.com

New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What’s the Latest?

February 14, 2024 | msn.com

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug

February 13, 2024 | finance.yahoo.com

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

April 18, 2024 | Priority Gold (Ad)

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

January 20, 2024 | benzinga.com

Anebulo Pharmaceuticals Stock (NASDAQ:ANEB) Dividends: History, Yield and Dates

January 8, 2024 | finance.yahoo.com

Anebulo Pharmaceuticals, Inc. (ANEB)

December 17, 2023 | nasdaq.com

Anebulo Pharmaceuticals (FRA:214) Price Target Increased by 21.00% to 6.80

December 9, 2023 | morningstar.com

Anebulo Pharmaceuticals Inc ANEB

November 21, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)

November 17, 2023 | markets.businessinsider.com

Buy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication Treatment

November 15, 2023 | msn.com

Anebulo Pharmaceuticals GAAP EPS of -$0.10 beats by $0.02

November 14, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

November 6, 2023 | finance.yahoo.com

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

October 19, 2023 | msn.com

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?

October 11, 2023 | benzinga.com

Director at Anebulo Pharmaceuticals Acquires Company Stock Options Worth 26,097 Shares

October 6, 2023 | marketwatch.com

Anebulo Pharmaceuticals Names Richie Cunningham as CEO

October 6, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

October 6, 2023 | finance.yahoo.com

Anebulo Pharmaceuticals Announces New CEO

September 25, 2023 | msn.com

HC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy Recommendation

September 25, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)

September 23, 2023 | nasdaq.com

Maxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy Recommendation

September 22, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)

See More Headlines

Receive ANEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ANEB
CUSIP: N/A
CIK: 1815974
Web: www.anebulo.com
Phone: 512-598-0931
Fax: N/A
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.67
High Stock Price Target: $8.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +123.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -109.40%
Return on Assets: -98.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.72
Quick Ratio: 6.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.41 per share
Price / Book: 7.27

Miscellaneous

Outstanding Shares: 25,630,000
Free Float: 3,614,000
Market Cap: $76.38 million
Optionable: Not Optionable
Beta: -1.00

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Joseph F. Lawler M.D. (Age 52)
Ph.D., Founder & Chairman
Comp: $11k
Dr. Kenneth C. Cundy Ph.D. (Age 65)
Chief Scientific Officer
Comp: $425.15k
Mr. Richard Anthony Cunningham (Age 53)
CEO & Director
Mr. Daniel V. George (Age 54)
Principal Accounting Officer, Acting CFO & Secretary
Mr. Scott L. Anderson
Head of Investor Relations & Public Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANEB Stock Analysis - Frequently Asked Questions

Should I buy or sell Anebulo Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares.
View ANEB analyst ratings or view top-rated stocks.
What is Anebulo Pharmaceuticals' stock price target for 2024?: 3 analysts have issued 1 year price objectives for Anebulo Pharmaceuticals' stock. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's share price to reach $6.67 in the next year. This suggests a possible upside of 133.9% from the stock's current price.
View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts.
How have ANEB shares performed in 2024?: Anebulo Pharmaceuticals' stock was trading at $2.42 at the start of the year. Since then, ANEB stock has increased by 17.8% and is now trading at $2.85.
View the best growth stocks for 2024 here.
Are investors shorting Anebulo Pharmaceuticals?: Anebulo Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 18,800 shares, an increase of 308.7% from the March 15th total of 4,600 shares. Based on an average trading volume of 5,600 shares, the short-interest ratio is presently 3.4 days. Currently, 0.2% of the company's shares are sold short.
View Anebulo Pharmaceuticals' Short Interest.

When is Anebulo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ANEB earnings forecast.
How were Anebulo Pharmaceuticals' earnings last quarter?: Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its earnings results on Tuesday, February, 13th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11).
When did Anebulo Pharmaceuticals IPO?: Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO.
How do I buy shares of Anebulo Pharmaceuticals?: Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANEB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis

Anebulo Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

ANEB Stock Price History

ANEB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ANEB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™